Neurocrine Biosciences, Inc. (NBIX) Expected to Post Earnings of $0.05 Per Share
Brokerages expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $0.05 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Neurocrine Biosciences’ earnings, with estimates ranging from ($0.21) to $0.39. Neurocrine Biosciences reported earnings per share of ($0.51) during the same quarter last year, which would suggest a positive year over year growth rate of 109.8%. The firm is scheduled to announce its next earnings report on Tuesday, February 13th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($2.00) to ($1.31). For the next year, analysts expect that the firm will post earnings of ($0.24) per share, with EPS estimates ranging from ($1.36) to $2.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the company earned ($0.43) earnings per share.
In related news, insider Dimitri E. Grigoriadis sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the insider now directly owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the sale, the insider now directly owns 84,596 shares in the company, valued at $6,010,545.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,405 shares of company stock worth $8,588,519. Company insiders own 4.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of NBIX. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares in the last quarter. Stephens Inc. AR bought a new stake in Neurocrine Biosciences during the 2nd quarter valued at approximately $207,000. Comerica Bank bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $210,000. Ardsley Advisory Partners bought a new stake in Neurocrine Biosciences during the 2nd quarter valued at approximately $230,000. Finally, Cubist Systematic Strategies LLC boosted its position in Neurocrine Biosciences by 151.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock valued at $244,000 after acquiring an additional 3,193 shares in the last quarter.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up $1.45 on Thursday, hitting $81.73. The company had a trading volume of 895,351 shares, compared to its average volume of 819,827. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences has a one year low of $38.43 and a one year high of $83.57.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.